Brief: Shanghai Junshi Biosciences Says Toripalimab Injection Were Successfully Included In Category B
Nov 28 (Reuters) - Shanghai Junshi Biosciences
688180.SS :
* TORIPALIMAB INJECTION WERE SUCCESSFULLY INCLUDED IN
CATEGORY B
OF NATIONAL DRUG LIST FOR BASIC MEDICAL INSURANCE
Further company coverage: 688180.SS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Junshi Biosciences
See all newsBrief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Receives Supplemental Drug Approval From NMPA
Brief: Shanghai Junshi Biosciences's Shareholder Plans To Cut Stake
Brief: Shanghai Junshi Biosciences Gets NMPA Acceptance Notice Of Supplemental Application For Toripalimab